Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation

被引:29
|
作者
Nelson, Winnie W. [1 ]
Wang, Li [2 ]
Baser, Onur [3 ,4 ]
Damaraju, Chandrasekharrao V. [5 ]
Schein, Jeffrey R. [1 ]
机构
[1] Janssen Sci Affairs LLC, Hlth Econ & Outcomes Res HECOR, Raritan, NJ 08869 USA
[2] STATinMED Res, Plano, TX USA
[3] STATinMED Res, Ann Arbor, MI USA
[4] MEF Univ, Istanbul, Turkey
[5] Janssen Res & Dev LLC, Raritan, NJ USA
关键词
Atrial fibrillation; Clinical outcomes; International normalized ratio; USA; US veterans; Warfarin; RISK-FACTOR; ANTICOAGULATION CONTROL; ANTITHROMBOTIC THERAPY; ORAL ANTICOAGULANT; PREDICTING STROKE; INTENSITY; HOSPITALS; QUALITY;
D O I
10.1007/s11096-014-0038-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Although efficacious in stroke prevention in non-valvular atrial fibrillation, many warfarin patients are sub-optimally managed. Objective To evaluate the association of international normalized ratio control and clinical outcomes among new warfarin patients with non-valvular atrial fibrillation. Setting Adult non-valvular atrial fibrillation patients (a parts per thousand yen18 years) initiating warfarin treatment were selected from the US Veterans Health Administration dataset between 10/2007 and 9/2012. Method Valid international normalized ratio values were examined from the warfarin initiation date through the earlier of the first clinical outcome, end of warfarin exposure or death. Each patient contributed multiple in-range and out-of-range time periods. Main outcome measure The relative risk ratios of clinical outcomes associated with international normalized ratio control were estimated. Results 34,346 patients were included for analysis. During the warfarin exposure period, the incidence of events per 100 person-years was highest when patients had international normalized ratio < 2:13.66 for acute coronary syndrome; 10.30 for ischemic stroke; 2.93 for transient ischemic attack; 1.81 for systemic embolism; and 4.55 for major bleeding. Poisson regression confirmed that during periods with international normalized ratio < 2, patients were at increased risk of developing acute coronary syndrome (relative risk ratio: 7.9; 95 % confidence interval 6.9-9.1), ischemic stroke (relative risk ratio: 7.6; 95 % confidence interval 6.5-8.9), transient ischemic attack (relative risk ratio: 8.2; 95 % confidence interval 6.1-11.2), systemic embolism (relative risk ratio: 6.3; 95 % confidence interval 4.4-8.9) and major bleeding (relative risk ratio: 2.6; 95 % confidence interval 2.2-3.0). During time periods with international normalized ratio > 3, patients had significantly increased risk of major bleeding (relative risk ratio: 1.5; 95 % confidence interval 1.2-2.0). Conclusion In a Veterans Health Administration non-valvular atrial fibrillation population, exposure to out-of-range international normalized ratio values was associated with significantly increased risk of adverse clinical outcomes.
引用
收藏
页码:53 / 59
页数:7
相关论文
共 50 条
  • [1] Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation
    Winnie W. Nelson
    Li Wang
    Onur Baser
    Chandrasekharrao V. Damaraju
    Jeffrey R. Schein
    International Journal of Clinical Pharmacy, 2015, 37 : 53 - 59
  • [2] Out-of-range international normalized ratio values and healthcare cost among new warfarin patients with non-valvular atrial fibrillation
    Nelson, Winnie W.
    Wang, Li
    Baser, Onur
    Damaraju, C. V.
    Schein, Jeffrey R.
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (05) : 333 - 340
  • [3] Association of Out-of-Range International Normalized Ratio (INR) Values and Adverse Clinical Outcomes Among Newly Initiated Warfarin Patients With Non-Valvular Atrial Fibrillation and Comorbid Diabetes
    Nelson, Winnie W.
    Wang, Li
    Baser, Onur
    Damaraju, C. V.
    Schein, Jeffrey R.
    CIRCULATION, 2014, 130
  • [4] Warfarin in non-valvular atrial fibrillation
    Dalby, A. J.
    Wessels, P.
    Opie, L. H.
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2013, 103 (12): : 901 - 904
  • [5] Impact of stroke risk factors on warfarin prescription among patients with non-valvular atrial fibrillation
    Zhao, Yu-Hui
    Zhang, Ting
    Du, Xin
    Wen, Dan
    Shang, Mei-Sheng
    Ma, Chang-Sheng
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (08): : 16587 - 16595
  • [6] Use of Warfarin in Elderly Patients With Non-Valvular Atrial Fibrillation - Subanalysis of the J-RHYTHM Registry -
    Kodani, Eitaro
    Atarashi, Hirotsugu
    Inoue, Hiroshi
    Okumura, Ken
    Yamashita, Takeshi
    Origasa, Hideki
    CIRCULATION JOURNAL, 2015, 79 (11) : 2345 - 2352
  • [7] Patterns of international normalized ratio values among new warfarin patients with nonvalvular atrial fibrillation
    Nelson, Winnie W.
    Milentijevic, Dejan
    Wang, Li
    Baser, Onur
    Damaraju, C. V.
    Schein, Jeffrey R.
    BLOOD COAGULATION & FIBRINOLYSIS, 2016, 27 (08) : 899 - 906
  • [8] Long-term PT-INR levels and the clinical events in the patients with non-valvular atrial fibrillation: A special reference to low-intensity warfarin therapy
    Takarada, Ken
    Sato, Masahito
    Goto, Masayuki
    Saito, Atsushi
    Ikeda, Yoshio
    Fujita, Satoru
    Fuse, Koichi
    Takahashi, Minoru
    Oguro, Takeo
    Matsushita, Hirooki
    Kitazawa, Hitoshi
    Okabe, Masaaki
    Abe, Hiroshi
    Toba, Ken
    Yamashina, Akira
    Aizawa, Yoshifusa
    JOURNAL OF CARDIOLOGY, 2014, 64 (02) : 127 - 132
  • [9] New anticoagulants in patients with non-valvular atrial fibrillation
    Zellerhoff, S.
    Lewalter, T.
    Eckardt, L.
    Treszl, A.
    Wegscheider, K.
    Breithardt, G.
    NERVENHEILKUNDE, 2012, 31 (11) : 813 - 820
  • [10] INR optimization based on stroke risk factors in patients with non-valvular atrial fibrillation
    Chung, Jee Eun
    Choi, Yoo Ri
    Seong, Jong Mi
    La, Hyen O.
    Gwak, Hye Sun
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2015, 37 (06) : 1038 - 1046